Atorvastatin: A potent new HMG-CoA reductase inhibitor

Cardiovascular Reviews and Reports

Volumn 19, Issue 5, 1998, Pages 32-48

  Hilleman, Daniel E ^a,c   Seyedroubari, Ali ^b  

^a CREIGHTON UNIVERSITY   (United States)

^b CREIGHTON UNIVERSITY CARDIAC CENTER   (United States)

^c CREIGHTON UNIVERSITY SCHOOL OF PHARMACY AND HEALTH PROFESSIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ATORVASTATIN; COLESTIPOL; CYCLOSPORIN; CYTOCHROME P450; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NEW DRUG; NICOTINIC ACID; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ABDOMINAL PAIN; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSTIPATION; DIET THERAPY; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DYSPEPSIA; FLATULENCE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERCHOLESTEROLEMIA; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; REVIEW;

EID: 0031924315     PISSN: 01973118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Vital Statistics of the United States, 1980. Volume II-Mortality, Part A. Hyattsville, MD: National Center for Health Statistics. 1985. Public Health Service publication DHHS (PHS) 85-1101.
2. Goldman L, Cook EF. The decline in ischemic heart disease mortality rates: An analysis of the comparative effects of medical interventions and changes in lifestyle. Ann Intern Med. 1984;101:825-836.
3. Kannel WB, Thom TJ. Declining cardiovascular mortality. Circulation. 1985;70:331-336.
4. Kannel WB, Castelli WP, GordonT, et al. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham Study. Ann Intern Med. 1981;74:1-2.
5. Newman WP III, Freedman DS, Voors AW, et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis: The Bogalusa Heart Study. N Engl J Med. 1986;314:138-144.
6. Neaton JD, Blackburn H, Jacobs D, et al. Serum cholesterol and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med. 1992;152: 1490-1500.
7. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;90:1329-1445.
8. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther. 1994;16:366-385.
9. Ginsberg HN. Update on the treatment of hypercholesterolemia, with a focus on HMG-CoA reductase inhibitors and combination regimens. Clin Cardiol. 1995; 18:307-315.
10. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
11. Shepard J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
12. Sacks FM, Pfeffer MA, Mave LA, et al. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335(14):1001-1009.
13. Parke-Davis Pharmaceuticals. Atorvastatin (Lipitor®) oral package insert. Ann Arbor, MI: 1996.
14. Blum CBB. Comparison of properties of four inhibitors of 3-hydroxy-3-methyglutaryl-coenzyme A reductase. Am J Cardiol. 1994;73(suppl D):3D-11D.
15. Conde K, Vergara-Jinenez M, Krause BR, et al. Hypercholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig. J Lipid Res. 1996;37: 2372-2382.
16. Alberts AW. Effects of HMG CoA reductase inhibitors on cholesterol synthesis. Drug Invest. 1990;2 (suppl 2):9-17.
17. Jungnickel PW, Cantral KA, Maloney PA. Drug review: Pravastatin: A new drug for the treatment of hypercholesterolemia. Clin Pharm 1992;11:677-689.
18. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996;275:128-133.
19. Kasim SE, LeBoeuf RC, Khilnani S, et al. Mechanisms of triglyceride-lowering effect of HMG-CoA reductase inhibitors in a hypertriglyceridemic animal model, the Zucker obese rat. J Lipid Res. 1992;33:1-7.
20. Davidson MH, Stein EA, Dujovne CA, et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol. 1997;79(1):38-42.
21. Cilla Jr DD, Whitfield LR, Gibson DM, et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, healthy subjects. Pharmacol Ther. 1997;60:687-695.
22. Cilla DD Jr, Radulovic LL, Whitfield LR, et al. Safety, tolerance, and pharmacokinetic (PK) profiles following single dose of CI-981, a potent HMG-CoA reductase inhibitor (abstr). Pharm Res. 1993;10(suppl):S-332.
23. Radulovic LL, Cilla DD, Posvar EL. Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. J Clin Pharmacol. 1995;35:990-994.
24. Michnievicz BM, Black AE, Sinz MW, et al. In vitro and in vivo metabolism of atorvastatin (CI-981) (abstr). ISSX Proc. 1994;6:93.
25. Cilla DD Jr, Gibson DM, Whitfield LR, et al. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol. 1995;36:604-609.
26. Gibson DM, Bron NJ, Richens A, et al. Effect of age and gender on pharmacokinetics of atorvastatin in humans (437340). J Clin Pharmacol. 1995;36:242-246.
27. Gibson DM, Yang B-B, Abel RB, et al. Effect of hepatic and renal impairment on pharmacokinetics (PK) and pharmacodynamics (PD) of atorvastatin (abstr). Pharm Res. 1995;13(9 suppl):5428.
28. Heinonen TM, Stein E, Weiss SR, et al. The lipid-lowering effects of atorvastatin, a new HMG-CoA Reductase inhibitor: Results of a double-masked study. Clin Ther. 1996;18(5):853-863.
29. Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group Efficacy of atorvastatin in primary hypercholesterolemia. Am J Cardiol. 1997;79:1248-1252.
30. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-82.
31. Gmerek A, Yang R, Bays H, et al. Atorvastatin causes a dose-dependent reduction in LDL-C and triglycerides (abstr). In: 66th Congress of the European Atherosclerosis Society Abstract Book. 1996 Jul 13-7: Florence, Italy; 212.
32. Bristol-Myers Squibb, Co. Pravastatin (Pravachol®) oral package insert. Princeton, NJ; 1993.
33. Merck & Co. Lovastatin (Mevacor®) oral package insert. West Point, PA; 1992.
34. Merck & Co. Simvastatin (Zocor®) oral package insert. West Point, PA; 1993.
35. Sandoz Pharmaceutical Co. Fluvastatin (Lescol®) oral package insert. East Hanover, NJ; 1994.
36. Heinonen T, Schrott H, McKenney J, et al. Atorvastatin, a new HMG-CoA reductase inhibitor as monotherapy and combined with colestipol. J Cardiovasc Pharmacol Ther. 1996;1:117-22.
37. Heinonen T, Black D. Atorvastatin monotherapy and combination therapy in the treatment of severe hypercholesterolemia (abstr). Atherosclerosis. 1995;115 (suppl):S20.
38. Bertolini S, Bittolo Bon G, Campbell LM, et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 1997;130:191-197.
39. Dart A, Jerums G, Nicholson G, et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997;80:39-44.
40. Davidson M, McKenney J, Stein E, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol. 1997;79:1475-1481.
41. Jones PH for the CURVES Investigators Comparison of the dose efficacy of atorvastatin with pravastatin, simvastatin, fluvastatin, and lovastatin - The CURVES study. Eur Heart J. 1997;18:371.
42. McKenney JM, McCormick LS, Kafonek S, et al. Lipid lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor, and niacin in patients with combined or isolated hypertriglyceridemia. Parke-Davis, Ann Arbor, MI, USA. (Data on file)
43. Ooi TC, Heinonen T, Alaupovic P, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: Comparison with fenofibrate. Arterioscler Thromb Vasc Biol. 1997. In press.
44. Naoumova RP, Marais D, Firth JC, et al. Atrovastatin augments therapy of homozygous familial hypercholesterolemia by inhibiting upregulation of cholesterol synthesis after apheresis and bile acid sequestrants (abstr). Circulation. 1997;94(8 suppl):1583.
45. Best JD, Nicholson GC, O'Neal DN, et al. Atorvastatin and simvastatin reduce elevated cholesterol in non-insulin dependent diabetes. Diabetes Nutr Metab. 1997;9(2):74-80.
46. Nawrocki J, Schwartz S, Fayyad R, et al. Atorvastatin, a new HMG-CoA reductase inhibitor, is safe and effective in NIDDM patients with hyperlipidemia. In: Abstracts of the 66th congress of the European Atherosclerosis Society, Florence, July 13-17, 1996. Houston: Giovanni Lorenzini Medical Foundation; 1966;222.
47. Gerson RJ, MacDonald JS, Alberts AW, et al. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Exp Eye Res. 1990;50:65-78.
48. Haria M, McTavish D. Pravastatin: A reappraisal of its pharmacological properties and therapeutic use in the management of coronary heart disease. Drugs 1997;53(2):299-336.
49. Plosher GL, Wagstaff AJ. Fluvastatin: A review of its pharmacology and use in the management of hypercholesterolaemia. Drugs. 1995;51:433-59.
50. Plosker GL, McTavish D. Simvastatin: A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Drugs. 1995 Aug;50:334-63.
51. Henwood JM, Heel RC. Lovastatin: A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs. 1988;36:429-54.
52. Yang BB, Hounslow NJ, Sedman AJ, et al. Effects of atorvastatin, an HMG-CoA reductase inhibitor, on hepatic oxidative metabolism of antipyrine. J Clin Pharmacol 1995;36:356-360.
53. Yang B-B, Smithers JA, Siedlik PH, et al. Atorvastatin pharmacokinetic interactions with other CYP3A4 substrates: erythromycin and ethinyl estradiol (abstr). Pharm Res. 1996;13(9)(suppl):S437.
54. Yang B-B, Smithers JA, Abel RB, et al. Effects of Maalox TC® on pharmacokinetics and pharmacodynamics of atorvastatin (abstr). Pharm Res. 1996; (suppl 9):S437.
55. Jackson G. Statins and coronary artery disease - It's the clinical endpoints that count. Br J Clin Pract. 1997;51:2-3.
56. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med. 1996;100:605-610.
57. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals. Am J Med. 1996; 100:197-204.
58. Price-Chek PCTM Computer version 2.16. St. Louis, MO: Medi-Span; 1977.